more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential

Research Report
  ()
D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. (COYA:NASDAQ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS.
Tags: Biotechnology / Pharmaceuticals

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1

  ()
BioMarin Pharmaceuticals Inc. (BMRN:NASDAQ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth.
Tags: Biotechnology / Pharmaceuticals

FDA Rejects Melanoma Drug Again as Analysts Slash Targets and Approval Path Comes Under Fire

  ()
Replimune Group Inc. (REPL:NASDAQ) received a second FDA rejection for RP1 in advanced melanoma, prompting analyst downgrades, price target cuts, and renewed debate over approval standards for cancer therapies.
Tags: Biotechnology / Pharmaceuticals

Sublingual Drug Reformulator Expands into Caffeine Market and Gets Capital Injection

Contributed Technical Analyst Opinion
  ()
Technical Analyst Stewart Thomson reviews Aspire Biopharma Holdings, Inc. (ASBP:NASDAQ) in light of its recent news.
Tags: Biotechnology / Pharmaceuticals

Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results

  ()
Niagen Bioscience Inc. (NAGE:NASDAQ) reports a 3% increase in total net sales to US$31.5 million for the first quarter. Read why analysts recommend this stock in a rapidly expanding market.
Tags: Biotechnology / Pharmaceuticals

Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst

Research Report
  ()
Wedbush Securities reiterated a Neutral rating on Novocure Ltd. (NVCR:NASDAQ) after the company posted a Q1/26 revenue beat of US$174.1 million, raised FY26 guidance to US$690710 million, and reported encouraging early Optune Pax launch metrics.
Tags: Biotechnology / Pharmaceuticals

MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA

Research Report
  ()
Wedbush Securities downgraded Replimune Group Inc. (NASDAQ:REPL) to NEUTRAL after the FDA issued a second complete response letter for RP1 in PD-1 refractory melanoma.
Tags: Biotechnology / Pharmaceuticals

Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results

  ()
Novocure Ltd. (NVCR:NASDAQ) posted 12% revenue growth, strong international patient gains, FDA momentum, and promising pancreatic cancer trial results in 2026.
Tags: Biotechnology / Pharmaceuticals

Three AI-Driven Cancer Programs Advance Toward Key 2026 Milestones

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) reported 2025 financial results and outlined progress across its kt-5000, kt-3283, and kt-2000 programs, alongside financing, leadership updates, and ongoing AI partnerships.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

Biotech Downgraded to Neutral After Second FDA CRL for Reproxalap in Dry Eye Disease

Research Report
  ()
H.C. Wainwright & Co. downgraded Aldeyra Therapeutics Inc. (ALDX:NASDAQ) to Neutral and slashed its price target after the company received a second FDA Complete Response Letter for its Reproxalap NDA in dry eye disease.
Tags: Biotechnology / Pharmaceuticals

Biotech Co. Faces Mounting ELEVIDYS Efficacy Risk as Roche Phase 3 Study Threatens US Franchise

Research Report
  ()
H.C. Wainwright analysts argue that Roche's new placebo-controlled Phase 3 study of ELEVIDYS, while aimed at reopening the European market, creates significant downside risk for Sarepta Therapeutics Inc.'s (SRPT:NASDAQ) core U.S. ambulatory business by potentially generating another failed NSAA readout.
Tags: Biotechnology / Pharmaceuticals

Wedbush Sees Denifanstat as Front-Line Acne Therapy with 249% Upside Potential

Research Report
  ()
Wedbush Securities analyst Dr. Yun Zhong reiterated a price target on Sagimet Biosciences (SGMT:NASDAQ), implying roughly 249% upside.
Tags: Biotechnology / Pharmaceuticals

California Biopharma Co. Uncovers Massive Oncology Breakthrough

  ()
Nurix Therapeutics Inc. (NRIX:NASDAQ) new cancer pipeline data highlights powerful targeted protein degradation advances, with analysts projecting 92% upside potential.
Tags: Biotechnology / Pharmaceuticals

Biopharma Advances High-Impact, First-of-Its-Kind Neuroreparative Drug

  ()
NervGen Pharma Corp. (NGEN:TSX.V; NGENF:OTCQX) drug produced sustained neurologic and functional gains in chronic tetraplegia, positioning it for pivotal Phase 3 development.
Tags: Biotechnology / Pharmaceuticals

Brisbane Biotech Showcases Degrader Pipeline Advantages at AACR

Research Report
  ()
Nurix Therapeutics (NASDAQ: NRIX) recently showcased AACR presentations that highlighted the mechanistic superiority of the company's protein degrader platform and preclinical data across key pipeline assets, NX-1607, NRX-4972.
Tags: Biotechnology / Pharmaceuticals

AI-Designed Cancer Drug Shows In Vivo Results, Brain Penetration

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) reported new preclinical data across two oncology programs at the AACR Annual Meeting, including ATR-mTOR inhibitor efficacy and kt-3283 formulation progress.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

Asceniv Growth, Margin Expansion, and Pipeline Optionality Drive Price Target

Research Report
  ()
Canaccord Genuity initiates coverage of ADMA Biologics Inc. (ADMA:NASDAQ), citing Asceniv's differentiated hyperimmune IVIG profile, accelerating margins from yield enhancement, and an underappreciated pipeline.
Tags: Biotechnology / Pharmaceuticals

Company Wins Back Promising Eye Disease Drug and Eyes Two Product Launches by 2028

Research Report
  ()
MeiraGTx Holdings plc. (MGTX:NASDAQ) reported three-year durability data for AAV-hAQP1 in radiation-induced xerostomia, the reacquisition of filing-ready XLRP asset bota-vec from Johnson & Johnson, and a US$100M, according to an H.C. Wainwright research note.
Tags: Biotechnology / Pharmaceuticals

Genetic Medicines Co. Reveals Transformative 'Only-of-Its-Kind' AAV Therapy Milestone

  ()
MeiraGTx Holdings Plc (MGTX:NASDAQ) reports 3-year gene therapy results, secures US$100M funding, and advances late-stage pipeline, signaling major commercial potential.
Tags: Biotechnology / PharmaceuticalsRegenerative Medicine

Massachusetts Biotech Co. Faces Major Melanoma Drug Setback

  ()
Replimune Group Inc.'s (REPL:NASDAQ) RP1 melanoma therapy hits FDA rejection, raising uncertainty around approval timelines and future market potential.
Tags: Biotechnology / Pharmaceuticals

MA Biotech Co. Downgraded to Sell After Second FDA CRL for RP-1 Melanoma BLA

Research Report
  ()
H.C. Wainwright downgraded Replimune Group (REPL:NASDAQ) to Sell after the FDA issued a second Complete Response Letter for the RP-1 plus Opdivo BLA in anti-PD1 failed melanoma.
Tags: Biotechnology / Pharmaceuticals

Biotech Firm Advances Voice-Based Intoxication Tech Aiming to Revolutionize Medical Diagnostics

  ()
MindBio Therapeutics Corp.'s (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) AI voice model analyzes 140+ biomarkers, targeting non-invasive impairment screening.
Tags: Biotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

What Do Analysts Think About the Biopharma Set on Transforming Psychiatry

  ()
Alto Neuroscience Inc. (ANRO:NYSE) is a clinical-stage biopharmaceutical company focused on transforming psychiatry through novel drug candidates.
Tags: Biotechnology / Pharmaceuticals

Canadian Biotech Co. Appoints Elite Regulatory Expert for Chile Expansion

  ()
MindBio Therapeutics Corp. (MBIO:CSE; MBQIF:OTCQB; WF6:Frankfurt) appoints Chilean policy leader Felipe Leyton for the mining rollout of its AI impairment detection tech.
Tags: Medical DevicesBiotechnology / PharmaceuticalsLife Sciences Tools & Diagnostics

San Francisco Pharma Co.'s HORIZON Phase 2 Data Validates APOL1 Path to Pivotal Trial

Research Report
  ()
H.C. Wainwright reiterated its rating and price target on Maze Therapeutics (MAZE:NASDAQ), following KOL calls that validated the HORIZON Phase 2 dataset as biologically coherent, confirmed the diabetic cohort signal as drug-attributable proof of concept, and outlined a clear path to pivotal trials.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 77 Next